Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
Status:
Recruiting
Trial end date:
2022-07-15
Target enrollment:
Participant gender:
Summary
Anemia affects between 20 and 50 % of women in the postpartum period. It is associated with
several adverse health consequences, such as impaired physical work capacity, deficits in
cognitive function and mood, reduced immune function and reduced duration of breastfeeding.
Postpartum anemia has also been shown to be a major risk factor for postpartum depression and
to significantly disrupt maternal-infant interactions. Iron deficiency is the principal cause
of anemia after delivery. Oral iron supplementation with ferrous sulfate has been considered
the standard of care with blood transfusion reserved for more severe or symptomatic cases. In
the last decade, two new intravenous iron compounds have been registered for clinical use:
ferric carboxymaltose (Iroprem®) and iron isomaltoside (Monofer®). No study to date compared
efficacy of iron carboxymaltose to iron isomaltoside for treatment of postpartum anemia.
The objective of the study is to compare efficacy of intravenous iron carboxymaltose to
intravenous iron isomaltoside and oral iron sulphate for treatment of postpartum anemia.